XCNQ
PSYG
, Last price
CAD
Name
Psyence Group Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
184.02%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-400k
L-99.42%
CFO
-6m
L+12.87%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Psyence Group, Inc. is a life science biotechnology company, which engages in the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. Its divisions include Psyence Production and Psyence Therapeutics. The company was founded by Jody Aufrichtig on March 26, 1994 and is headquartered in Toronto, Canada.
Key people
Chairman of the Board, Chief Executive Officer · since 2012
Andrew Hilton
Chief Financial Officer, Corporate Secretary · since 2013
Remo DiFronzo
Director · since 2013
Jeffrey Lowe
Director · since 2013
Peter MacLean
Director · since 2013
Headquarters & legal address
121 Richmond Street West
Toronto, ON M5H 2K1
CA
Toronto, ON M5H 2K1
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||